Rigosertib
Rigosertib (ON-01910) is a multi-kinase inhibitor and a selective anti-cancer agent, which induces apoptosis by inhibition the PI3 kinase/Akt pathway, promots the phosphorylation of histone H2AX and induces G2/M arrest in cell cycle[1][2]. Rigosertib is a selective and non-ATP-competitive inhibitor of PLK1 with an IC50 of 9 nM[3].
Product Specifications
CAS Number
[592542-59-1]
Product Name Alternative
ON-01910
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; PI3K; Polo-like Kinase (PLK)
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/rigosertib.html
Purity
99.01
Solubility
DMSO : 75 mg/mL (ultrasonic)
Smiles
COC1=CC=C(C=C1NCC(O)=O)CS(/C=C/C2=C(C=C(C=C2OC)OC)OC)(=O)=O
Molecular Formula
C21H25NO8S
Molecular Weight
451.49
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
PLK1; PLK2
Citation 01
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
